Trevi Therapeutics (TRVI) Research & Development (2018 - 2025)
Trevi Therapeutics (TRVI) posted quarterly Research & Development of $6.2 million for Q4 2025, down 33.61% year-over-year from $9.3 million in Q4 2024, and down 38.59% quarter-over-quarter from $10.1 million in Q3 2025.
Trevi Therapeutics (TRVI) Research & Development (2018 - 2025) Analysis & Trends
Trevi Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $6.2 million for Q4 2025.
- In Q4 2025, Research & Development fell 33.61% year-over-year to $6.2 million; the TTM figure through Dec 2025 stood at $35.0 million (down 11.13% YoY), while the FY2025 annual figure was $33.5 million, down 14.98% from the prior year.
- Research & Development for Q4 2025 stood at $6.2 million, down from $10.1 million in the prior quarter.
- The five-year high for Research & Development was $11.2 million in Q3 2024, with the low at $4.3 million in Q4 2022.
- The 5-year median for Research & Development is $6.2 million (2025), against an average of $6.9 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 77.51% in 2024, then plunged 33.61% in 2025.
- Trevi Therapeutics' Research & Development stood at $6.2 million in 2021, then tumbled by 30.13% to $4.3 million in 2022, then surged by 50.98% to $6.5 million in 2023, then surged by 43.11% to $9.3 million in 2024, then sank by 33.61% to $6.2 million in 2025.
- Business Quant data shows TRVI's Research & Development at $6.2 million in Q4 2025, $10.1 million in Q3 2025, and $9.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.19 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Jun 30, 2025 | 9.39 Mn |
| Dec 31, 2024 | 9.33 Mn |
| Sep 30, 2024 | 11.22 Mn |
| Jun 30, 2024 | 10.02 Mn |
| Mar 31, 2024 | 8.80 Mn |
| Dec 31, 2023 | 6.52 Mn |
| Sep 30, 2023 | 6.32 Mn |
| Jun 30, 2023 | 5.84 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 4.32 Mn |
| Sep 30, 2022 | 5.77 Mn |
| Jun 30, 2022 | 5.10 Mn |
| Mar 31, 2022 | 4.65 Mn |
| Dec 31, 2021 | 6.18 Mn |
| Sep 30, 2021 | 4.72 Mn |
| Jun 30, 2021 | 6.50 Mn |
| Mar 31, 2021 | 5.59 Mn |
| Dec 31, 2020 | 6.56 Mn |